Evidence map›Paper›PMID 35889990›Full record

ArticlePathogens (Basel, Switzerland)2022

Comparison of Bacterial Risk in Cryo AHF and Pathogen Reduced Cryoprecipitated Fibrinogen Complex.

Thea Lu, Pallavi Nahata, Aja Johnson, Nadia Keltner, Lindsay Peters, Melissa McCormack, Bianca Muñoz, Mary Krath, Elan Weiner, Peter Bringmann

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Thea LuCerus Corporation, Concord, CA 94520, USA.
Pallavi NahataCerus Corporation, Concord, CA 94520, USA.
Aja JohnsonCerus Corporation, Concord, CA 94520, USA.
Nadia KeltnerCerus Corporation, Concord, CA 94520, USA.
Lindsay PetersCerus Corporation, Concord, CA 94520, USA.
Melissa McCormackCerus Corporation, Concord, CA 94520, USA.
Bianca MuñozCerus Corporation, Concord, CA 94520, USA.ORCID 0000-0002-5248-1972
Mary KrathCerus Corporation, Concord, CA 94520, USA.
Elan WeinerCerus Corporation, Concord, CA 94520, USA.
Peter BringmannCerus Corporation, Concord, CA 94520, USA.
Cerus (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Until November 2020, cryoprecipitated antihaemophilic factor (cryo AHF) was the only United States Food and Drug Administration (FDA)-approved fibrinogen source to treat acquired bleeding. The post-thaw shelf life of cryo AHF is limited, in part, by infectious disease risk. Concerns over product wastage demand that cryo AHF is thawed as needed, with thawing times delaying the treatment of coagulopathic patients. In November 2020, the FDA approved Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. Pathogen Reduced Cryoprecipitated Fibrinogen Complex (also known as INTERCEPT

Indexed as

bacterial riskcryo AHFcryoprecipitated antihaemophilic factorfibrinogenhemorrhageINTERCEPTmassive transfusion protocol MTPpatient blood management PBMsepsistrauma

Identifiers

PMID35889990
PMCPMC9317717
OpenAlexW4283761865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.